113 related articles for article (PubMed ID: 22168663)
1. Combined C3b and factor B autoantibodies and MPGN type II.
Chen Q; Müller D; Rudolph B; Hartmann A; Kuwertz-Bröking E; Wu K; Kirschfink M; Skerka C; Zipfel PF
N Engl J Med; 2011 Dec; 365(24):2340-2. PubMed ID: 22168663
[No Abstract] [Full Text] [Related]
2. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.
Marinozzi MC; Roumenina LT; Chauvet S; Hertig A; Bertrand D; Olagne J; Frimat M; Ulinski T; Deschênes G; Burtey S; Delahousse M; Moulin B; Legendre C; Frémeaux-Bacchi V; Le Quintrec M
J Am Soc Nephrol; 2017 May; 28(5):1603-1613. PubMed ID: 28096309
[TBL] [Abstract][Full Text] [Related]
3. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
5. Factor H autoantibodies in membranoproliferative glomerulonephritis.
Goodship TH; Pappworth IY; Toth T; Denton M; Houlberg K; McCormick F; Warland D; Moore I; Hunze EM; Staniforth SJ; Hayes C; Cavalcante DP; Kavanagh D; Strain L; Herbert AP; Schmidt CQ; Barlow PN; Harris CL; Marchbank KJ
Mol Immunol; 2012 Oct; 52(3-4):200-6. PubMed ID: 22721707
[TBL] [Abstract][Full Text] [Related]
6. Screening for anti-factor B autoantibody in a patient with acute renal injury due to dense deposit disease.
Krmar RT; Skattum L; Bárány P; Józsi M
Clin Nephrol; 2012 Jan; 77(1):85-6. PubMed ID: 22185975
[No Abstract] [Full Text] [Related]
7. The role of complement in autoimmune renal disease.
Seelen MA; Daha MR
Autoimmunity; 2006 Aug; 39(5):411-5. PubMed ID: 16923541
[TBL] [Abstract][Full Text] [Related]
8. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
9. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
[TBL] [Abstract][Full Text] [Related]
10. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
11. Evidence that an autoantibody of IgG3 subclass against C3b discloses a C3 Nef activity in a pateint with partial lipodystrophy and glomerulonephritis.
Fontaine M; Daveau M; Lebreton JP; Dumouchel L; Vannier JP; Godin M
Ann Immunol (Paris); 1980; 131C(1):39-53. PubMed ID: 6901590
[TBL] [Abstract][Full Text] [Related]
12. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.
Kazatchkine MD; Fearon DT; Austen KF
J Immunol; 1979 Jan; 122(1):75-81. PubMed ID: 762425
[No Abstract] [Full Text] [Related]
13. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
14. Management of membranoproliferative glomerulonephritis type II with plasmapheresis.
Kurtz KA; Schlueter AJ
J Clin Apher; 2002; 17(3):135-7. PubMed ID: 12378549
[TBL] [Abstract][Full Text] [Related]
15. [Familial membranoproliferative glomerulonephritis].
Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
[TBL] [Abstract][Full Text] [Related]
16. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
Appel GB; Cook HT; Hageman G; Jennette JC; Kashgarian M; Kirschfink M; Lambris JD; Lanning L; Lutz HU; Meri S; Rose NR; Salant DJ; Sethi S; Smith RJ; Smoyer W; Tully HF; Tully SP; Walker P; Welsh M; Würzner R; Zipfel PF
J Am Soc Nephrol; 2005 May; 16(5):1392-403. PubMed ID: 15800116
[TBL] [Abstract][Full Text] [Related]
17. [Alternative complement activation pathway. Its mechanism, importance and quantitative determination].
Gancevici GG; Popescu C
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):209-21. PubMed ID: 6390651
[No Abstract] [Full Text] [Related]
18. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
19. Crescentic glomerulonephritis--which patients should be treated with plasma exchange?
Bell GM; Cumming AD; Swainson CP; Winney RJ; Robson JS
Life Support Syst; 1983; 1 Suppl 1():92-4. PubMed ID: 6336470
[No Abstract] [Full Text] [Related]
20. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
